Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-626 Ib/II study in systemic lupus erythematosus
CTR20253492Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 626 in systemic lupus erythematosus (SLE), sponsored by 3S Guojian Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
626
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20253492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253492.